The availability of 750 mcg teriparatide administered dose in AU remains restricted, primarily owing to its niche therapeutic use in addressing severe bone fragility. Market are primarily handled through specialist pharmacies and hospital settings, necessitating a medical order and qualified medical review. While obtained versions are available, ea